Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 583

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 583
---
 Closing Date and expiring on the tenth anniversary of the Gloperba-Elyxyb Closing Date (the “Gloperba-Elyxyb Payment Term”), Scilex Pharma shall pay to each Gloperba-Elyxyb RPA Purchaser, by wire transfer of immediately available funds in U.S. dollars to such Gloperba-Elyxyb RPA Purchaser’s account, such Gloperba-Elyxyb RPA Purchaser’s Specified Percentage (as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) of the Covered Product Revenue Payments (each as defined in the Gloperba-Elyxyb Royalty Purchase Agreement) for each calendar quarter no later than 60 calendar days after the end of each calendar quarter.

The Gloperba-Elyxyb Royalty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Gloperba-Elyxyb Payment Term.

The Company elected the fair value option for the Gloperba-Elyxyb Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of February 28, 2025 and March 31, 2025, the fair value of the ZTlido Royalty Purchase Agreement was $ 0.5 million, recorded as a purchased revenue liability on the unaudited condensed consolidated balance sheet.

8. Sorrento Stock Purchase Agreement Sorrento Stock Purchase Agreement On September 21, 2023, the Company entered into that certain Stock Purchase Agreement (the “Sorrento SPA”) with Sorrento Therapeutics, Inc. (“Sorrento”), the Company’s then-controlling stockholder, pursuant to which the F-82**

Company purchased from Sorrento (i) 1,716,245shares of Common Stock, (ii) 29,057,097shares of Series A Preferred Stock, par value $ 0.0001per share (the “Series A Preferred Stock”), and (iii) 1,386,617Public Warrants (as defined below), which are currently exercisable for an aggregate of up to 39,617shares of Common Stock and 3,104,000Private Warrants (collectively